Gilead SciencesGILD
GILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 18,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 19 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
38% more funds holding in top 10
Funds holding in top 10: 13 [Q2] → 18 (+5) [Q3]
24% more first-time investments, than exits
New positions opened: 167 | Existing positions closed: 135
18% more capital invested
Capital invested by funds: $73B [Q2] → $85.9B (+$12.9B) [Q3]
2% more funds holding
Funds holding: 1,645 [Q2] → 1,677 (+32) [Q3]
3% more call options, than puts
Call options by funds: $958M | Put options by funds: $928M
2.39% less ownership
Funds ownership: 84.75% [Q2] → 82.36% (-2.39%) [Q3]
10% less repeat investments, than reductions
Existing positions increased: 613 | Existing positions reduced: 682
Research analyst outlook
19 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$80
14%
downside
Avg. target
$101
9%
upside
High target
$125
35%
upside
19 analyst ratings
12 positive
63%
7 neutral
37%
0 negative
0%
Cantor Fitzgerald Olivia Brayer 54% 1-year accuracy 13 / 24 met price target | 14%downside $80 | Neutral Reiterated | 11 Dec 2024 |
RBC Capital Brian Abrahams 19% 1-year accuracy 15 / 79 met price target | 9%downside $84 | Sector Perform Reiterated | 11 Dec 2024 |
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 18%upside $109 | Buy Reinstated | 10 Dec 2024 |
Oppenheimer Matthew Biegler 0% 1-year accuracy 0 / 28 met price target | 24%upside $115 | Outperform Reiterated | 10 Dec 2024 |
UBS Colin Bristow 13% 1-year accuracy 2 / 16 met price target | 4%upside $96 | Neutral Maintained | 21 Nov 2024 |
Financial journalist opinion
Based on 31 articles about GILD published over the past 30 days
Neutral
Business Wire
15 hours ago
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and.
Positive
Zacks Investment Research
17 hours ago
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Positive
InvestorPlace
1 day ago
Cash is Down, Valuations Are Up, but Stay Invested
Bullish sentiment rules
Positive
Zacks Investment Research
2 days ago
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
Positive
Zacks Investment Research
2 days ago
5 High Earnings Yield Value Picks to Buy for 2025
Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD.
Positive
Seeking Alpha
3 days ago
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined with Gilead's robust HIV portfolio, position the company for significant revenue growth. Despite competition and debt, Gilead's financial health is solid, with substantial cash flow and manageable debt levels.
Positive
Zacks Investment Research
3 days ago
4 Big Drug Stocks That May Continue to Outperform in 2025
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
Neutral
Business Wire
3 days ago
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakthrough Therapy Designation is based on results from the global Phase 2 TROPiCS-03 study ES-SCLC cohort.
Neutral
Business Wire
4 days ago
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray's tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company's iterative approach applies AI-empowered methods to an.
Positive
Zacks Investment Research
4 days ago
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
Charts implemented using Lightweight Charts™